辨证选菌,还是菌群说了算?——个性化菌群干预 vs 一刀切干预的头对头证据

Written by

in

Language

Evidence level: B

一盒益生菌卖给所有人,与”一人一方”的辨证用药之间,差的不是商业理念,而是一类可以严格检验的统计学问题:分型选菌,到底比一刀切多带来多少获益?

正文

中医的”辨证论治”有个朴素前提:同样一种不适,张三和李四背后的失衡不一样,所以用药也不能一样。到了肠道菌群时代,这个前提遇到了一个现代版本的问题——益生菌该不该按体质分型来选?还是说,测一下菌群、按数据说话更可靠?答案是两者都需要,但要回答”哪个更好”,必须做一件事:把”按体质分型选菌”和”一刀切干预”放进同一个随机对照试验里,头对头比较。本文桥接的正是这个”辨证选菌增量价值”的证据现状。

先看一刀切干预的失败率,这是整个问题的起点。2024 年一项针对非便秘型肠易激综合征的多中心双盲安慰剂对照试验中,副干酪乳杆菌 DG 干预 12 周,临床应答率只有 25%——四分之三的人没有明显获益(PMID 38178601)。这不是个案,而是益生菌研究的普遍现象:同一株菌,有人有效有人无效。这篇研究更重要的发现是:应答者与无应答者在基线就有可测的菌群差异——应答者富集 Collinsella aerofaciens 等 18 个类群,而这些菌在应答者中干预后被显著压制,无应答者中则毫无变化。换句话说,”谁该吃哪种菌”的信息,藏在每个人的基线菌群里。

那么,能不能把”分型”做得更简单、更贴近临床?2024 年一项韩国随机双盲安慰剂对照试验给出了一条务实路径:不测基因,只问排便习惯——便秘型给通便配方(Consti-Biome),腹泻型给止泻配方(Sensi-Biome),4 周后两组的胃肠道症状和菌群组成(乳酸杆菌科、Erysipelotrichaceae 等 SCFA 生产者)都出现了与各自配方对应的改善(PMID 38435094)。这是”按表型分型选菌”的直接 RCT 证据:分型依据越简单,越接近中医体质问卷”望闻问切后填量表”的工作方式。

更前沿的是菌群测序驱动的个性化。2022 年一项功能性便秘试验中,50 名罗马 IV 标准确诊患者被随机分到”菌群分析+AI 辅助个体化膳食”组或常规治疗组,6 周后个性化组每周完全自主排便次数从 1.7 增至 4.3,提升 2.5 倍,88% 的患者 PAC-QoL 改善超过 50%,显著优于常规治疗组(PMID 36431088)。2024 年一项 121 人的多中心试验把菌群个性化膳食与金标准低 FODMAP 饮食头对头比较:两组 IBS 症状积分都显著下降,但个性化组在所有 IBS 亚型(便秘型、腹泻型、混合型)上表现更均衡,且带来了显著的菌群多样性改变(PMID 38717025)。这类”AI 测菌+开方”的试验证明:菌群信息确实能指导干预选择,且优于部分一刀切方案。

那中医体质在这个图景里处在什么位置?关键在于:体质与菌群指纹已经建立了稳定的关联(见《中医体质的肠道菌群特征》),而且辨证用药的菌群机制已有人体 RCT 证据。2024 年一项 120 名 2 型糖尿病患者的双盲试验中,葛根芩连汤显著降低糖化血红蛋白与空腹血糖,机制指向肠道 Faecalibacterium 富集与炎症因子下降(PMID 38495337);同年另一项失眠研究更直接——63 名失眠患者按两种中医证型(脾气虚、脾气虚兼胃热)分别用两首不同方剂,基线菌群组成即按证型分开,机器学习能仅凭菌群区分证型,且两方各按自己的菌群-炎症通路起效(PMID 38817449)。这提示”证型”确实对应着可测的菌群差异,而”辨证选干预”在菌群层面有真实生理基础。

把这些拼在一起,就得到一个清晰的实验设计蓝图:三臂 RCT——按九种体质分型选菌组、泛用益生菌组、安慰剂组,以体质量表评分复评和菌群指纹为双终点。它要回答的不是”益生菌有没有用”(已有 meta 证实,PMID 39598283),而是更锋利的问题:多花力气做体质分型,能否换来超越一刀切的增量获益? 目前的证据缺口恰恰在这里——分型选菌的 RCT 已有(按排便习惯、按菌群测序),中医体质分型与菌群的关联已有,但把两者接起来的头对头试验还不存在。

证据与局限

已验证: 益生菌干预存在大量无应答者,应答与基线菌群特征相关(PMID 38178601);按排便表型分型选菌可改善症状与菌群(PMID 38435094);菌群测序+AI 个性化膳食优于常规治疗且不劣于低 FODMAP 饮食(PMID 36431088、38717025);辨证用药的降糖、助眠效应有菌群机制支撑,证型对应可测菌群差异(PMID 38495337、38817449);菌群干预总体有效但效应异质性明显(PMID 39598283)。

部分验证: “中医体质分型×选菌”作为完整闭环的头对头 RCT 尚不存在;现有分型选菌试验用的是排便习惯或菌群测序,未纳入体质问卷。

待验证: 九种体质×选菌 vs 泛用菌群干预的三臂头对头 RCT;体质分型与菌群测序分型在同一数据集上对干预应答的预测力增量对比;体质导向选菌的应答者-无应答者分层特征。

相关阅读

证据等级: B(”分型选菌 vs 一刀切”的头对头 RCT 在排便表型与菌群测序两个版本上均已存在,中医体质分型与菌群关联亦有 RCT 支撑,但”体质分型×选菌”合一试验缺失,属强科学类比/间接证据)
参考文献: PMID 38178601, PMID 38435094, PMID 36431088, PMID 38717025, PMID 38495337, PMID 38817449, PMID 39598283


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Selecting Bacteria by Syndrome or Letting the Microbiome Decide? Head-to-Head Evidence on Personalized vs. One-Size-Fits-All Microbiome Interventions

Evidence level: B

Selling a single probiotic strain to everyone versus “treating according to pattern differentiation” differs not in commercial philosophy, but in a strictly testable statistical question: How much additional benefit does pattern-based strain selection provide over a one-size-fits-all approach?

Main Text

The TCM principle of “treating according to pattern differentiation” rests on a simple premise: while patients may share the same complaint, their underlying imbalances differ (e.g., Zhang San vs. Li Si), necessitating different treatments. In the era of gut microbiome research, this premise encounters a modern counterpart: Should probiotics be selected based on individual constitution types, or is it more reliable to sequence the microbiome and act on the data? The answer requires both approaches, but determining “which is superior” demands a specific experimental design: placing “pattern-based strain selection” and “one-size-fits-all intervention” within the same randomized controlled trial (RCT) for head-to-head comparison. This article bridges the current evidence landscape regarding the “incremental value of pattern-based strain selection.”

First, consider the failure rate of one-size-fits-all interventions, which serves as the starting point for this issue. In a 2024 multicenter double-blind placebo-controlled trial targeting non-constipated IBS, a 12-week intervention with Lactobacillus paracasei DG yielded a clinical response rate of only 25%—meaning three-quarters showed no significant benefit (PMID 38178601). This is not an isolated case but a common phenomenon in probiotic research: the same strain yields results for some but not others. A more significant finding from this study is that responders and non-responders exhibit measurable baseline microbiome differences: responders were enriched with 18 taxa including Collinsella aerofaciens, which were significantly suppressed post-intervention in responders but remained unchanged in non-responders. In other words, the information regarding “who should take which strain” is embedded within each individual’s baseline microbiome.

Can we simplify “pattern differentiation” to better align with clinical practice? A 2024 Korean randomized double-blind placebo-controlled trial offered a pragmatic pathway: without genetic sequencing, simply ask about bowel habits—constipation patients received a constipation-relief formula (Consti-Biome), while diarrhea patients received an anti-diarrheal formula (Sensi-Biome). After 4 weeks, both groups showed improvements in gastrointestinal symptoms and microbiome composition (e.g., Lactobacillaceae, SCFA producers in Erysipelotrichaceae) corresponding to their respective formulas (PMID 38435094). This provides direct RCT evidence for “pattern-based strain selection by phenotype”: the simpler the differentiation criteria, the closer it aligns with the TCM workflow of completing a questionnaire after “inspection, listening/smelling, inquiry, and palpation.”

More advanced is microbiome sequencing-driven personalization. In a 2022 trial for functional constipation, 50 patients diagnosed with Rome IV criteria were randomly assigned to a “microbiome analysis + AI-assisted personalized diet” group or a standard treatment group. After 6 weeks, the personalized group saw weekly complete bowel movements increase from 1.7 to 4.3 (a 2.5-fold rise), with 88% of patients showing >50% improvement in PAC-QoL, significantly outperforming the standard group (PMID 36431088). A 2024 multicenter trial involving 121 participants compared personalized microbiome diets against the gold-standard low FODMAP diet head-to-head: while symptom scores decreased significantly in both groups, the personalized group showed more balanced performance across all IBS subtypes (constipation, diarrhea, mixed) and induced significant changes in microbiome diversity (PMID 38717025). These “AI-based microbiome profiling + prescription” trials demonstrate that microbiome data can indeed guide intervention selection and outperform certain one-size-fits-all protocols.

Where does TCM constitution fit into this landscape? The key lies in the established stable association between constitution and microbiome fingerprints (see Gut Microbiome Characteristics of TCM Constitution), coupled with human RCT evidence supporting the microbiome mechanisms of pattern-based medication. In a 2024 double-blind trial involving 120 patients with type 2 diabetes, Ge Gen Qin Lian Tang significantly lowered HbA1c and fasting glucose, with mechanisms pointing toward enrichment of Faecalibacterium in the gut and reduced inflammatory factors (PMID 38495337); concurrently, another insomnia study from the same year was more direct—63 patients with insomnia were treated with two distinct formulas based on two TCM patterns (Spleen Qi Deficiency, or Spleen Qi Deficiency with Stomach Heat). Baseline microbiome composition was stratified by pattern, and machine learning could distinguish patterns based solely on microbiome data; furthermore, both formulas activated via their respective microbiome-inflammatory pathways (PMID 38817449). This suggests that “patterns” correspond to measurable microbiome differences, providing a genuine physiological basis for “pattern-based intervention selection” at the microbiome level.

Synthesizing these elements yields a clear experimental design blueprint: a three-arm RCT comprising a pattern-stratified strain selection group, a universal probiotic group, and a placebo group, with body constitution scores and microbiome fingerprints serving as dual endpoints. It does not ask “are probiotics effective?” (already confirmed by meta-analysis, PMID 39598283), but rather the sharper question: Does the effort invested in constitution stratification yield incremental benefits exceeding one-size-fits-all approaches? The current evidence gap lies precisely here—while RCTs for pattern-based strain selection exist (based on bowel habits or sequencing) and associations between TCM constitution and microbiomes are established, a head-to-head trial integrating both remains absent.

Evidence and Limitations

Verified: High non-response rates exist in probiotic interventions, with response correlated to baseline microbiome features (PMID 38178601); pattern-based selection by bowel phenotype improves symptoms and microbiome (PMID 38435094); microbiome sequencing + AI personalized diets outperform standard treatment and are non-inferior to low FODMAP diets (PMID 36431088, 38717025); mechanisms for blood sugar reduction and sleep improvement in pattern-based medication are supported by microbiome data, with patterns corresponding to measurable microbiome differences (PMID 38495337, 38817449); overall microbiome interventions are effective but exhibit high heterogeneity (PMID 39598283).

Partially Verified: A complete closed-loop head-to-head RCT for “TCM constitution stratification × strain selection” does not yet exist; existing pattern-based selection trials utilize bowel habits or sequencing but do not incorporate constitution questionnaires.

To Be Verified: A three-arm head-to-head RCT comparing nine-constitution stratified strain selection vs. universal microbiome intervention; comparative predictive power of constitution stratification vs. microbiome sequencing stratification for intervention response within the same dataset; responder/non-responder stratification characteristics for constitution-guided strain selection.

Related Reading

Evidence Level: B (“Pattern-based strain selection vs. one-size-fits-all” head-to-head RCTs exist for both bowel phenotype and sequencing versions; TCM constitution-microbiome associations are supported by RCTs, but a unified “constitution stratification × strain selection” trial is missing, constituting strong scientific analogy/indirect evidence)
References: PMID 38178601, PMID 38435094, PMID 36431088, PMID 38717025, PMID 38495337, PMID 38817449, PMID 39598283


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *